OCI-Ly3Homo sapiens (Human)Cancer cell line
Also known as: LY3, Ly3, OCILY3, OCI Ly3, OCI-Ly03, OCILY-3, OCI-Ly 3, Oci-Ly-3, OCI-LY-3, OCI-ly3, OCI-LY3, Ocl-Ly3
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_8800 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Bone marrow[UBERON:UBERON_0002371] |
Donor Information
| Age | 52 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Diffuse large B-cell lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Activated B-cell Type |
| OncoTree Code | ABC |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000158_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | MYD88 | p.Leu252Pro (c.755T>C) (L265P) | Heterozygous | - | PubMed=21179087 |
| MutationSimple | CARD11 | p.Leu251Pro (c.752T>C) (L244P) | Homozygous | - | Unknown, PubMed=18323416 |
| Gene fusion | IGH | IGH-SPIB | - | - | Unknown, PubMed=31160637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Clin. Cancer Res. 24:3967-3980(2018).
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Pham L.V.
Oncotarget 9:346-360(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
Tripsas C.K., Lindeman N.I., Treon S.P.
Blood 121:2051-2058(2013).
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Marra M.A.
Blood 122:1256-1265(2013).
Genetic heterogeneity of diffuse large B-cell lymphoma.";
Dunson D.B., Dave S.S.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
Leukemia 27:1381-1390(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Oncogenically active MYD88 mutations in human lymphoma.";
Chan W.-C., Staudt L.M.
Nature 470:115-119(2011).
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.
Blood 117:200-210(2011).
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Kutok J.L., Shipp M.A.
Blood 116:3268-3277(2010).
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Nature 463:88-92(2010).
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Robetorye R.S., Aguiar R.C.T.
Blood 113:6681-6690(2009).
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.";
Chan W.-C., Staudt L.M.
Science 319:1676-1679(2008).
Serologic detection of diffuse large B-cell lymphoma-associated antigens.
Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H.
Int. J. Cancer 110:563-569(2004).
Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.
Genes Chromosomes Cancer 33:225-234(2002).
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.
Nature 403:503-511(2000).
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
Leuk. Lymphoma 19:165-171(1995).